|Bid||173.48 x 800|
|Ask||173.57 x 800|
|Day's range||172.69 - 174.79|
|52-week range||155.72 - 186.69|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||23.41|
|Earnings date||19 Jul 2022|
|Forward dividend & yield||4.52 (2.58%)|
|Ex-dividend date||23 May 2022|
|1y target est||190.39|
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.
Meanwhile, things are even worse for the growth-dependent Nasdaq Composite (NASDAQINDEX: ^IXIC). Following its all-time high in November 2021, the Nasdaq has tumbled 27%. The Nasdaq's tumble officially places it in a bear market.